RDRupal Dhariwal

Rupal Dhariwal

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Rupal Dhariwal has a total of 20 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Decoding eggplant fruit: Multi-omics profiling of caffeoyl-CoA-3-OMT expression

    by Kirtan Dave, Prashant Kaushik, Nil Patil, Rupal Dhariwal, Meenakshi Sharma, Alpa Yadav, Parmdeep Singh Dhanda, Mukul Jain


  • Insilico and invitro profiling of curcumin and its derivatives as a potent acetylcholinesterase inhibitor

    by Mukul Jain, Rupal Dhariwal, Krupanshi Bhardava, Sarvjeet Das, Mushtaque Shaikh, Reshma Tendulkar, Rashmi Wani, Meenakshi Sharma, Anil Kumar Delta, Prashant Kaushik


  • Open Access

    Unveiling the Molecular Footprint: Proteome-Based Biomarkers for Alzheimer’s Disease

    by Mukul Jain, Rupal Dhariwal, Nil Patil, Sandhya Ojha, Reshma Tendulkar, Mugdha Tendulkar, Parmdeep Singh Dhanda, Alpa Yadav, Prashant Kaushik

    Alzheimer’s disease (AD) is a devastating neurodegenerative disorder characterized by progressive cognitive decline and memory loss. Early and accurate diagnosis of AD is crucial for implementing timely interventions and developing effective therapeutic strategies. Proteome-based biomarkers have emerged as promising tools for AD diagnosis and prognosis due to their ability to reflect disease-specific molecular alterations. There is of great significance for biomarkers in AD diagnosis and management. It emphasizes the limitations of existing diagnostic approaches and the need for reliable and accessible biomarkers. Proteomics, a field that comprehensively analyzes the entire protein complement of cells, tissues, or bio fluids, is presented as a powerful tool for identifying AD biomarkers. There is a diverse range of proteomic approaches employed in AD research, including mass spectrometry, two-dimensional gel electrophoresis, and protein microarrays. The challenges associated with identifying reliable biomarkers, such as sample heterogeneity and the dynamic nature of the disease. There are well-known proteins implicated in AD pathogenesis, such as amyloid-beta peptides, tau protein, Apo lipoprotein E, and clusterin, as well as inflammatory markers and complement proteins. Validation and clinical utility of proteome-based biomarkers are addressing the challenges involved in validation studies and the diagnostic accuracy of these biomarkers. There is great potential in monitoring disease progression and response to treatment, thereby aiding in personalized medicine approaches for AD patients. There is a great role for bioinformatics and data analysis in proteomics for AD biomarker research and the importance of data preprocessing, statistical analysis, pathway analysis, and integration of multi-omics data for a comprehensive understanding of AD pathophysiology. In conclusion, proteome-based biomarkers hold great promise in the field of AD research. They provide valuable insights into disease mechanisms, aid in early diagnosis, and facilitate personalized treatment strategies. However, further research and validation studies are necessary to harness the full potential of proteome-based biomarkers in clinical practice.